Table 2.
Laboratory-based measures in cohort without known NAFLD, stratified by glycemic control
| Glycemic control groupsc | |||
|---|---|---|---|
| Mean HbA1c <8.5% (n = 39) | Mean HbA1c 8.5-9.5% (n = 67) | Mean HbA1c >9.5% (n = 106) | |
| Liver enzyme testing | |||
| AST, mean (SD)d | 22.9 (8.0) | 23.0 (18.0) | 19.3 (7.3) |
| ALT, mean (SD)d | 36.4 (12.2) | 36.0 (21.9) | 34.0 (11.9) |
| ALT >40 IU/L, n (%)d | 16 (44.4) | 16 (29.1) | 38 (42.2) |
| Platelet count, mean (SD)e | 236.2 (63.1) | 258.9 (57.4) | 260.3 (61.8) |
| Undiagnosed NAFLDa, n (%) | 6 (15.4) | 8 (11.9) | 22 (20.8) |
| Undiagnosed NAFLDb, n (%) | 15 (38.5) | 19 (28.4) | 43 (40.6) |
| FIB-4 score, mean (SD)f | 1.4 (1.4) | 1.0 (0.4) | 0.9 (0.5) |
| FIB-4 score risk categories | |||
| Low risk, n (%) | 24 (72.7) | 42 (85.7) | 72 (93.5) |
| Indeterminate risk, n (%)c | 7 (21.2) | 7 (14.3) | 5 (6.5) |
| High risk, n (%) | 2 (6.1) | 0 (0) | 0 (0) |
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4.
a Based on Kanwal et al. criteria (ALT ≥40 IU/mL in males, ALT ≥31 IU/mL in females at least 6 months apart) [19].
b Based on Prati et al. criteria for healthy ALT ranges (ALT ≥30 IU/mL in males, ALT ≥19 IU/mL in females at least 6 months apart) [20].
c 1 individual did not have a measurable A1c collected thus is excluded from this table.
d 31 individuals had no AST or ALT values measured (3 with HbA1c <8.5%, 12 with HbA1c 8.5-9.5%, and 16 with HbA1c >9.5%).
e 47 individuals had no platelets measured (5 with HbA1c <8.5%, 18 with HbA1c 8.5-9.5% and 24 in with HbA1c >9.5%).
f 53 individuals had no FIB-4 score calculated due to missing values (6 with HbA1c <8.5%, 18 with HbA1c 8.5-9.5%, and 29 with HbA1c >9.5%). We used liver enzymes and platelets collected within 3 months of each other for FIB-4 calculation.